U.S. markets closed

Avacta Group Plc (AVCT.L)

LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
Add to watchlist
105.00-3.50 (-3.23%)
At close: 04:35PM BST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close108.50
Bid103.00 x 0
Ask105.00 x 0
Day's Range101.00 - 105.75
52 Week Range1.17 - 181.90
Avg. Volume2,020,793
Market Cap268.031M
Beta (5Y Monthly)1.88
PE Ratio (TTM)N/A
EPS (TTM)-10.50
Earnings DateSep 28, 2022 - Oct 03, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est155.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AVCT.L

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      LG Chem Renews License Triggering Payment to Avacta

      LONDON & WETHERBY, England, June 30, 2022--Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that LG Chem Life Sciences (LG Chem), the life sciences division of the South Korean LG Group, has exercised its renewal option as part of the ongoing collaboration with Avacta, triggering a license renewal fee payment to Avacta of $2 m

    • Simply Wall St.

      Even though Avacta Group (LON:AVCT) has lost UK£39m market cap in last 7 days, shareholders are still up 304% over 3 years

      The Avacta Group Plc ( LON:AVCT ) share price has had a bad week, falling 12%. But over three years the performance has...

    • Business Wire

      Avacta Announces AffyXell Joint Venture Milestone and Increased Equity Stake

      CAMBRIDGE & WETHERBY, England, April 13, 2022--Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a milestone equity payment has been triggered resulting in an increase in Avacta’s shareholding in AffyXell Therapeutics ("AffyXell"), a joint venture between Avacta and Daewoong Pharmaceutical ("Daewoong") in South Korea.